Literature DB >> 25917084

Endoplasmic Protein Nogo-B (RTN4-B) Interacts with GRAMD4 and Regulates TLR9-Mediated Innate Immune Responses.

Toshifumi Kimura1, Shota Endo1, Masanori Inui1, Shin-Ichiroh Saitoh2, Kensuke Miyake2, Toshiyuki Takai3.   

Abstract

TLRs are distributed in their characteristic cellular or subcellular compartments to efficiently recognize specific ligands and to initiate intracellular signaling. Whereas TLRs recognizing pathogen-associated lipids or proteins are localized to the cell surface, nucleic acid-sensing TLRs are expressed in endosomes and lysosomes. Several endoplasmic reticulum (ER)-resident proteins are known to regulate the trafficking of TLRs to the specific cellular compartments, thus playing important roles in the initiation of innate immune responses. In this study, we show that an ER-resident protein, Nogo-B (or RTN4-B), is necessary for immune responses triggered by nucleic acid-sensing TLRs, and that a newly identified Nogo-B-binding protein (glucosyltransferases, Rab-like GTPase activators and myotubularins [GRAM] domain containing 4 [GRAMD4]) negatively regulates the responses. Production of inflammatory cytokines in vitro by macrophages stimulated with CpG-B oligonucleotides or polyinosinic:polycytidylic acid was attenuated in the absence of Nogo-B, which was also confirmed in serum samples from Nogo-deficient mice injected with polyinosinic:polycytidylic acid. Although a deficiency of Nogo-B did not change the incorporation or delivery of CpG to endosomes, the localization of TLR9 to endolysosomes was found to be impaired. We identified GRAMD4 as a downmodulator for TLR9 response with a Nogo-B binding ability in ER, because our knockdown and overexpression experiments indicated that GRAMD4 suppresses the TLR9 response and knockdown of Gramd4 strongly enhanced the response in the absence of Nogo-B. Our findings indicate a critical role of Nogo-B and GRAMD4 in trafficking of TLR9.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917084     DOI: 10.4049/jimmunol.1402006

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway.

Authors:  Yikui Tian; Eric J Charles; Zhen Yan; Di Wu; Brent A French; Irving L Kron; Zequan Yang
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-05       Impact factor: 5.209

2.  Microglial Homeostasis Requires Balanced CSF-1/CSF-2 Receptor Signaling.

Authors:  Violeta Chitu; Fabrizio Biundo; Gabriel G L Shlager; Eun S Park; Ping Wang; Maria E Gulinello; Şölen Gokhan; Harmony C Ketchum; Kusumika Saha; Michael A DeTure; Dennis W Dickson; Zbignew K Wszolek; Deyou Zheng; Andrew L Croxford; Burkhard Becher; Daqian Sun; Mark F Mehler; E Richard Stanley
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

3.  Nogo-B promotes epithelial-mesenchymal transition in lung fibrosis via PERK branch of the endoplasmic reticulum stress pathway.

Authors:  Ying Zhu; Meng Yang; Xue-Hui Li; Wu-Jian Xu; Wei Gao; Yu-Han Chen; Jian-Dong Li; Qiang Li
Journal:  Ann Transl Med       Date:  2021-04

4.  NOGO-A/RTN4A and NOGO-B/RTN4B are simultaneously expressed in epithelial, fibroblast and neuronal cells and maintain ER morphology.

Authors:  Olli Rämö; Darshan Kumar; Erika Gucciardo; Merja Joensuu; Maiju Saarekas; Helena Vihinen; Ilya Belevich; Olli-Pekka Smolander; Kui Qian; Petri Auvinen; Eija Jokitalo
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

5.  Gene variations in autism spectrum disorder are associated with alteration of gut microbiota, metabolites and cytokines.

Authors:  Zhi Liu; Xuhua Mao; Zhou Dan; Yang Pei; Rui Xu; Mengchen Guo; Kangjian Liu; Faming Zhang; Junyu Chen; Chuan Su; Yaoyao Zhuang; Junming Tang; Yankai Xia; Lianhong Qin; Zhibin Hu; Xingyin Liu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

6.  GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.

Authors:  Qian Yun Ge; Jin Chen; Gan Xun Li; Xiao Long Tan; Jia Song; Deng Ning; Jie Mo; Peng Cheng Du; Qiu Meng Liu; Hui Fang Liang; Ze Yang Ding; Xue Wu Zhang; Bi Xiang Zhang
Journal:  Clin Transl Med       Date:  2021-11

7.  IFITM3 restricts virus-induced inflammatory cytokine production by limiting Nogo-B mediated TLR responses.

Authors:  M Clement; J L Forbester; M Marsden; P Sabberwal; M S Sommerville; D Wellington; S Dimonte; S Clare; K Harcourt; Z Yin; L Nobre; R Antrobus; B Jin; M Chen; S Makvandi-Nejad; J A Lindborg; S M Strittmatter; M P Weekes; R J Stanton; T Dong; I R Humphreys
Journal:  Nat Commun       Date:  2022-09-08       Impact factor: 17.694

8.  The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways.

Authors:  M Duhamel; F Rodet; A N Murgoci; R Desjardins; H Gagnon; M Wisztorski; I Fournier; R Day; M Salzet
Journal:  Sci Rep       Date:  2016-01-18       Impact factor: 4.379

9.  Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.

Authors:  Hao Cai; Hexige Saiyin; Xing Liu; Dingding Han; Guoqing Ji; Bo Qin; Jie Zuo; Suqin Shen; Wenbo Yu; Jiaxue Wu; Yanhua Wu; Long Yu
Journal:  Mol Oncol       Date:  2018-10-26       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.